home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

A Novel Strategy For Regulating Gene Expression

 
  September, 28 2004 13:10
your information resource in human molecular genetics
 
     
Researchers at Children's Hospital Boston and Harvard Medical School have created a novel, elegant, and safer system for controlling gene expression - turning genes on and off as needed - that involves an intervention as simple as giving a drug. Potentially, with this technique, a gene could even be activated by natural conditions in the body - for example, in a diabetic patient, a rise in glucose concentration would automatically turn on the gene responsible for insulin production.

The system, described in a proof-of-principle paper in the Sept. 23 edition of the journal Nature, is simpler than current methods of gene regulation, and the technology exists to make it work with virtually any drug, making it suitable for a broad range of therapeutic and research applications.

The technique involves inserting a special DNA sequence into a patient's own genes, or into a gene introduced by gene therapy. This sequence encodes a ribozyme, a sequence of RNA that has the unique ability to spontaneously cut itself in half. The ribozyme becomes part of the gene's messenger RNA (mRNA), the template that carries instructions for making the protein encoded by that gene. When the ribozyme cuts itself in half, the mRNA is cut in half, too - disabling it and, in effect, turning off the gene. Inhibiting ribozyme breakage, which can be done with various drugs, leaves the mRNA intact; this allows the gene to turn ''on'' and make the desired protein - such as a hormone or growth factor needed by the body.

''Perhaps the most exciting aspect of the new work is that, in conjunction with other technologies, we will likely be able to 'tailor' gene regulation systems to respond to any drug or chemical,'' says Dr. Richard Mulligan, director of gene therapy research at Children's Hospital Boston and director of the Harvard Gene Therapy Initiative. ''Ultimately, the system should also enable the 'release' of a therapeutically useful protein in response to changing concentrations of chemicals in cells. For instance, it may be possible to develop a gene therapy whereby cells are engineered to secrete insulin in response to a rise in glucose. Such 'biological sensing' could have a wide range of applications.''

Current methods of gene regulation usually involve a complicated three-part system that requires a ''promoter'' (a DNA sequence near the gene that allows it to transfer its information to RNA), a specialized activating protein that makes the promoter work, and a drug that, in turn, enables the activating protein. Together, these elements turn the gene on and off. However, there are concerns that the activating protein could trigger the immune system and cause unwanted side effect. In addition, the current systems work with only a handful of specific drugs. In contrast, the ribozyme-based system can, in principle, be designed to regulate genes using any drug, or any chemical change in the body. The system is also easier to turn on and off than existing systems, allowing a treatment to be stopped for safety reasons.

''With recent concerns about the development of leukemia in several children treated with gene therapy, this new method adds an important new safety feature to the gene therapy toolbox,'' says Mulligan, who is also a professor of genetics at Harvard Medical School.

Dr. Laisang Yen and other members of Mulligan's laboratory began by evaluating hundreds of known ribozymes, and found two that function well in human cells. One ribozyme was especially prone to cutting itself in two, and the researchers tweaked it to make it even more efficient. Next, they identified two compounds that strongly inhibit ribozyme self-cutting, and showed that they could be used to turn on ribozyme-containing genes in mammalian cells, inducing the cells to make the desired protein. Finally, they proved that the technique works in live animals. They introduced the gene for a protein called luciferase, containing an embedded ribozyme, into the retinas of mice. When they treated the mice with a ribozyme-inhibiting drug, the gene turned on and the animals' retinas began producing luciferase. Without the drug, the gene remained ''off,'' and no luciferase was produced.

Ribozymes occur naturally in plants, animals, and bacteria. Recent studies suggest that bacteria use ribozymes to regulate their own gene activity, by ''sensing'' and reacting to changing levels of natural compounds in their environment. Scientists have theorized that these ribozymes might have evolved before proteins did and functioned as an ancient gene-control system. Mulligan, Yen and colleagues have taken the first step to demonstrate that this natural system could be adapted and exploited to treat human disease.

Yen L, Svendsen J, Lee JS, Gray JT, Magnier M, Baba T, D'Amato RJ, Mulligan RC.
Exogenous control of mammalian gene expression through modulation of RNA self-cleavage.
Nature. 2004 Sep 23;431(7007):471-6.


CHILDREN'S HOSPITAL BOSTON
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults for over 100 years. More than 500 scientists, including eight members of the National Academy of Sciences, nine members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. Founded in 1869 as a 20-bed hospital for children, Children's Hospital Boston today is a 300-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital visit: www.childrenshospital.org.

HARVARD MEDICAL SCHOOL
http://www.hms.harvard.edu/
Harvard Medical School has more than 5,000 full-time faculty working in eight academic departments based at the School's Boston quadrangle or in one of 47 academic departments at 18 Harvard teaching hospitals and research institutes. Those Harvard hospitals and research institutions include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Hospital, The CBR Institute for Biomedical Research, Children's Hospital Boston, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Mental Health Center, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, VA Boston Healthcare System.

- ### -

Copyright © 2004, Children's Hospital Boston. All rights reserved.


Message posted by: Frank S. Zollmann

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.